Characteristics of cord blood recipients for 297 patients with negative HLA antibody and 89 patients with positive HLA antibody
| . | Negative anti-HLA IgG . | Positive anti-HLA IgG . | P . | ||
|---|---|---|---|---|---|
| N . | % . | N . | % . | ||
| Number of transplants | 297 | 89 | |||
| Patient age at transplantation | < .0001 | ||||
| Median (range) | 33 | (0-69) | 46 | (0-68) | |
| Patient sex | < .0001 | ||||
| Male | 166 | (55.9) | 22 | (24.7) | |
| Female | 131 | (44.1) | 67 | (75.3) | |
| Sex matching | .001 | ||||
| Matched | 146 | (49.2) | 46 | (51.7) | |
| Male to female | 66 | (22.2) | 33 | (37.1) | |
| Female to male | 85 | (28.6) | 10 | (11.2) | |
| Disease | .002 | ||||
| ALL | 109 | (36.7) | 18 | (20.2) | |
| AML | 122 | (41.1) | 47 | (52.8) | |
| ATL | 11 | (3.7) | 4 | (4.5) | |
| MDS | 17 | (5.7) | 12 | (13.5) | |
| CML | 9 | (3.0) | 6 | (6.7) | |
| NHL | 28 | (9.4) | 2 | (2.2) | |
| MM | 1 | (0.3) | 0 | (0.0) | |
| Disease status* | .13 | ||||
| Standard | 124 | (41.8) | 44 | (49.4) | |
| Advanced | 168 | (56.6) | 41 | (46.1) | |
| Unknown | 5 | (1.7) | 4 | (4.5) | |
| Human leukocyte antigen matching (A, B, DR) | |||||
| No. of serologically mismatched loci | |||||
| Graft-versus-host disease direction | .27 | ||||
| 0 | 34 | (11.4) | 17 | (19.1) | |
| 1 | 131 | (44.1) | 38 | (42.7) | |
| 2 | 131 | (44.1) | 34 | (38.2) | |
| 3 | 1 | (0.3) | 0 | (0.0) | |
| Rejection direction | .75 | ||||
| 0 | 36 | (12.1) | 10 | (11.2) | |
| 1 | 124 | (41.8) | 33 | (37.1) | |
| 2 | 136 | (45.8) | 46 | (51.7) | |
| 3 | 1 | (0.3) | 0 | (0.0) | |
| ABO matching | .36 | ||||
| Matched | 98 | (33.0) | 36 | (40.4) | |
| Minor mismatch | 71 | (23.9) | 17 | (19.1) | |
| Major mismatch | 128 | (43.1) | 35 | (39.3) | |
| Unknown | 0 | (0.0) | 1 | (1.1) | |
| Number of nucleated cells infused, ×107/kg | .61 | ||||
| Median (range) | 2.58 | (0.64-20.8) | 2.56 | (1.65-13.9) | |
| Number of CD34+ cells infused, ×105/kg | .041 | ||||
| Median (range) | 0.88 | (0.06-9.44) | 0.80 | (0.17-3.82) | |
| GVHD prophylaxis | .66 | ||||
| Cyclosporine based | 174 | (58.6) | 48 | (53.9) | |
| Tacrolimus based | 111 | (37.4) | 38 | (42.7) | |
| Other | 12 | (4.0) | 3 | (3.4) | |
| MTX for GVHD prophylaxis | .72 | ||||
| No | 68 | (22.9) | 22 | (24.7) | |
| Yes | 229 | (77.1) | 67 | (75.3) | |
| G-CSF | .71 | ||||
| No | 20 | (6.7) | 7 | (7.9) | |
| Yes | 277 | (93.3) | 82 | (92.1) | |
| . | Negative anti-HLA IgG . | Positive anti-HLA IgG . | P . | ||
|---|---|---|---|---|---|
| N . | % . | N . | % . | ||
| Number of transplants | 297 | 89 | |||
| Patient age at transplantation | < .0001 | ||||
| Median (range) | 33 | (0-69) | 46 | (0-68) | |
| Patient sex | < .0001 | ||||
| Male | 166 | (55.9) | 22 | (24.7) | |
| Female | 131 | (44.1) | 67 | (75.3) | |
| Sex matching | .001 | ||||
| Matched | 146 | (49.2) | 46 | (51.7) | |
| Male to female | 66 | (22.2) | 33 | (37.1) | |
| Female to male | 85 | (28.6) | 10 | (11.2) | |
| Disease | .002 | ||||
| ALL | 109 | (36.7) | 18 | (20.2) | |
| AML | 122 | (41.1) | 47 | (52.8) | |
| ATL | 11 | (3.7) | 4 | (4.5) | |
| MDS | 17 | (5.7) | 12 | (13.5) | |
| CML | 9 | (3.0) | 6 | (6.7) | |
| NHL | 28 | (9.4) | 2 | (2.2) | |
| MM | 1 | (0.3) | 0 | (0.0) | |
| Disease status* | .13 | ||||
| Standard | 124 | (41.8) | 44 | (49.4) | |
| Advanced | 168 | (56.6) | 41 | (46.1) | |
| Unknown | 5 | (1.7) | 4 | (4.5) | |
| Human leukocyte antigen matching (A, B, DR) | |||||
| No. of serologically mismatched loci | |||||
| Graft-versus-host disease direction | .27 | ||||
| 0 | 34 | (11.4) | 17 | (19.1) | |
| 1 | 131 | (44.1) | 38 | (42.7) | |
| 2 | 131 | (44.1) | 34 | (38.2) | |
| 3 | 1 | (0.3) | 0 | (0.0) | |
| Rejection direction | .75 | ||||
| 0 | 36 | (12.1) | 10 | (11.2) | |
| 1 | 124 | (41.8) | 33 | (37.1) | |
| 2 | 136 | (45.8) | 46 | (51.7) | |
| 3 | 1 | (0.3) | 0 | (0.0) | |
| ABO matching | .36 | ||||
| Matched | 98 | (33.0) | 36 | (40.4) | |
| Minor mismatch | 71 | (23.9) | 17 | (19.1) | |
| Major mismatch | 128 | (43.1) | 35 | (39.3) | |
| Unknown | 0 | (0.0) | 1 | (1.1) | |
| Number of nucleated cells infused, ×107/kg | .61 | ||||
| Median (range) | 2.58 | (0.64-20.8) | 2.56 | (1.65-13.9) | |
| Number of CD34+ cells infused, ×105/kg | .041 | ||||
| Median (range) | 0.88 | (0.06-9.44) | 0.80 | (0.17-3.82) | |
| GVHD prophylaxis | .66 | ||||
| Cyclosporine based | 174 | (58.6) | 48 | (53.9) | |
| Tacrolimus based | 111 | (37.4) | 38 | (42.7) | |
| Other | 12 | (4.0) | 3 | (3.4) | |
| MTX for GVHD prophylaxis | .72 | ||||
| No | 68 | (22.9) | 22 | (24.7) | |
| Yes | 229 | (77.1) | 67 | (75.3) | |
| G-CSF | .71 | ||||
| No | 20 | (6.7) | 7 | (7.9) | |
| Yes | 277 | (93.3) | 82 | (92.1) | |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATL, adult T-cell leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; GVHD, graft-versus-host disease; MTX, methotrexate; and G-CSF, granulocyte colony-stimulating factor.
Standard risk: 1st and 2nd complete remission of AML, 1st complete remission of ALL, 1st chronic phase of CML, refractory anemia of MDS, 1st complete remission of lymphoproliferative diseases.